INTRODUCTION
Currently, there are no clear guidelines on the management of Rosai-Dorfman disease (rdd). Radiotherapy has been one of various therapeutic modalities used in the treatment of rdd, but there is a paucity of information describing the radiotherapy technique, dose, and fractionation, and the relative success of its use. Furthermore, advances in the delivery of external-beam radiation warrant the reporting of recent radiotherapeutic approaches to the management of rdd. Here, we contribute a case in which rdd of the larynx was put into complete remission with radiotherapy.
CASE DESCRIPTION
A 92-year-old woman presented with progressive stridor, exertional dyspnea, massive bilateral lymphadenopathy, and a nasopharyngeal mass. She was e159 Current OnCOlOgy-VOlume 18, number 3
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The foregoing factors were considered in planning the total radiation dose and number of fractions eventually used: 25 Gy in 10 fractions, with a boost of 5 Gy to the gross tumour volume delivered in 2 fractions [ Figure 3(A,B) ]. External-beam radiation was delivered using a 3-dimensional conformal approach, with posterior-anterior and right and left oblique and lateral beams.
The prescribed treatment was well tolerated with minimal acute toxicity: mild dysphagia and fatigue.
Neither a pureed diet nor analgesics were required. Using the Radiation Therapy Oncology Group scoring system, those symptoms quantify as grade 1 acute radiation morbidity of the pharynx, esophagus, and larynx. No acute toxicity to the skin was observed. Fibre-optic examination 1 week after treatment revealed mild erythema of the laryngeal mucosa and thickened secretions, with complete resolution of the patient's airway symptoms.
The radiotherapy was successful in putting the extranodal rdd into long-term remission. One year post radiotherapy, the patient underwent head-andneck computed tomography that was negative for lesions at the sites previously affected by the subglottic rdd (Figure 4 ). Follow-up continued for 2 years without any clinical or radiologic findings suggestive of local recurrence.
DISCUSSION
Rosai and Dorfman first described 4 cases of the clinicopathologic entity known as sinus histiocytosis with massive lymphadenopathy in 1969 1,2 . This benign disorder usually affects young adults and children, with no predilection by sex. Presentation with large bilateral painless cervical lymphadenopathy, with or without fever, is the hallmark of this condition, occurring in 89% of cases 1,2 . Extranodal involvement occurs in fewer than half of cases and is more common in elderly patients 3 . Skin, nasal cavity or paranasal sinuses, soft tissue, orbit, and bone are the most frequently seen sites of extranodal rdd 4 . Lymphadenopathy usually accompanies extranodal rdd; however, isolated extranodal presentations of this entity in various head-and-neck anatomic sites have been described 5 .
Important in the diagnosis of rdd is the demonstration, upon pathology examination, of emperipolesis of leukocytes and concurrent histiocytosis 1 . Histiocytes in rdd lesions have abundant cytoplasm. As well, molecular features have been noted in rdd lesions; immunohistochemistry reveals the presence of CD1a, CD68, CD163, α 1 -antichymotrypsin and S-100 6, 7 .
No ideal treatment protocol exists for the management of rdd. Initial management usually consists of either incisional or excisional biopsy, followed by observation in most cases. Further surgical management is usually reserved for recurrent lesions causing functional disability or obstruction of critical structures. Corticosteroids are frequently used, with approximately one third of patients achieving a complete (cr) or partial (pr) response to treatment 7 . Chemotherapy (single agents and combinations) has been used with limited success. Various classes of chemotherapeutic agents have been used, including alkylating agents, antimetabolites, and vinca alkaloids.
Extranodal rdd of the larynx has been documented in the literature [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In these cases, treatment was initiated because of symptoms such as stridor, dysphagia, dysphonia, and dyspnea because of a laryngeal lesion. Subglottic rdd was treated by radiation therapy in only 1 of the cases, with no evidence of disease recurrence at 16 months' follow-up 10 .
In 1990, 418 cases of rdd were reviewed by Komp 8 . Radiotherapy treatment was documented in 34 patients, but the radiation dose was reported in only 18. In 5 The controversy about whether a radiation dose-response relationship exists for rdd lesions cannot currently be resolved for several reasons, including missing treatment data, poor reporting of radiation cases, infrequent use of radical radiation doses, and the rarity of this disease entity. In a review of the recent literature since the publication of the Komp review, we identified 4 cases of rdd lesions that responded to radiation (Table i) 20-23 . Although those cases do not assist with the issue of the proper dose-fractionation schedule for rdd lesions, they do provide some evidence that, in selected cases, disease recurrence can be prevented or delayed with the use of either primary or postoperative radiotherapy.
CONCLUSIONS
A steroid-resistant subglottic rdd lesion causing respiratory distress responded well to externalbeam radiotherapy, with durable symptom control. A multidisciplinary approach to the management of primary and recurrent rdd lesions is required to provide good local control and functional results for individual patients. Reporting of future cases treated 
